- Home
- TBLD vs NRIX Comparison
TBLD vs NRIX Comparison
Compare TBLD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- NRIX
- Stock Information
- Founded
- TBLD 2021
- NRIX 2009
- Country
- TBLD United States
- NRIX United States
- Employees
- TBLD N/A
- NRIX N/A
- Industry
- TBLD Investment Managers
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- NRIX Health Care
- Exchange
- TBLD Nasdaq
- NRIX Nasdaq
- Market Cap
- TBLD 643.6M
- NRIX 728.6M
- IPO Year
- TBLD N/A
- NRIX 2020
- Fundamental
- Price
- TBLD $20.19
- NRIX $9.75
- Analyst Decision
- TBLD
- NRIX Strong Buy
- Analyst Count
- TBLD 0
- NRIX 14
- Target Price
- TBLD N/A
- NRIX $29.07
- AVG Volume (30 Days)
- TBLD 77.7K
- NRIX 1.2M
- Earning Date
- TBLD 01-01-0001
- NRIX 10-09-2025
- Dividend Yield
- TBLD 6.21%
- NRIX N/A
- EPS Growth
- TBLD N/A
- NRIX N/A
- EPS
- TBLD N/A
- NRIX N/A
- Revenue
- TBLD N/A
- NRIX $88,381,000.00
- Revenue This Year
- TBLD N/A
- NRIX $74.59
- Revenue Next Year
- TBLD N/A
- NRIX N/A
- P/E Ratio
- TBLD N/A
- NRIX N/A
- Revenue Growth
- TBLD N/A
- NRIX 41.86
- 52 Week Low
- TBLD $15.80
- NRIX $8.18
- 52 Week High
- TBLD $20.55
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TBLD 56.99
- NRIX 55.10
- Support Level
- TBLD $19.70
- NRIX $8.20
- Resistance Level
- TBLD $20.45
- NRIX $10.23
- Average True Range (ATR)
- TBLD 0.32
- NRIX 0.47
- MACD
- TBLD 0.01
- NRIX 0.18
- Stochastic Oscillator
- TBLD 73.19
- NRIX 76.41
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.